Genetics, pathogenesis and clinical interventions in type 1 diabetes

Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide. Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-associated complications. The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans. Integrating these advances has led to the recognition that the balance between regulatory and effector T cells determines disease risk, timing of disease activation, and disease tempo. Here we describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.

[1]  C. Janeway,et al.  Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. , 2004, Diabetes.

[2]  D. Bluemke,et al.  Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). , 2012, The American journal of cardiology.

[3]  H. Mcdevitt,et al.  Expansion of Functional Endogenous Antigen-Specific CD4+CD25+ Regulatory T Cells from Nonobese Diabetic Mice1 , 2005, The Journal of Immunology.

[4]  R. Ley,et al.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes , 2008, Nature.

[5]  A. Moore,et al.  In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression , 2008, Magnetic resonance in medicine.

[6]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[7]  J. Todd,et al.  Rare Variants of IFIH1, a Gene Implicated in Antiviral Responses, Protect Against Type 1 Diabetes , 2009, Science.

[8]  K. Yamagata,et al.  Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. , 1993, The Journal of clinical investigation.

[9]  Christophe Benoist,et al.  Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters , 2009, Nature Medicine.

[10]  Kara Hunter,et al.  Type 1 diabetes genes and pathways shared by humans and NOD mice. , 2005, Journal of autoimmunity.

[11]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[12]  J. Petersen,et al.  Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. , 1999, Immunity.

[13]  D. Vignali,et al.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. , 2009, Immunity.

[14]  N. Morgan,et al.  The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes , 2009, Diabetologia.

[15]  G. Karsenty,et al.  CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET Results of a Multicentre Double-blind Trial , 1986, The Lancet.

[16]  J. Voltarelli,et al.  Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials , 2009, Diabetology & metabolic syndrome.

[17]  A. Hämäläinen,et al.  Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study , 2005, Diabetologia.

[18]  P. Hougaard,et al.  Long-term risk of IDDM in first-degree relatives of patients with IDDM , 1994, Diabetologia.

[19]  R. Tisch,et al.  B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. , 1998, Journal of immunology.

[20]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[21]  J. Todd,et al.  HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk , 2008, Diabetes.

[22]  S. Ziegler,et al.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations. , 2006, The Journal of clinical investigation.

[23]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[24]  E. Sprecher,et al.  Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. , 2001, Diabetes care.

[25]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[26]  M. Peakman,et al.  Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group , 2010, Clinical and experimental immunology.

[27]  Bhagirath Singh,et al.  BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. , 1997, Journal of autoimmunity.

[28]  W. Hagopian,et al.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.

[29]  D. Zélénika,et al.  CD4 T cells can reject major histocompatibility complex class I‐incompatible skin grafts , 1999, European journal of immunology.

[30]  S. Richardson,et al.  Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.

[31]  D. Serreze,et al.  The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice , 2005, Immunological reviews.

[32]  H. Jun,et al.  A new look at viruses in type 1 diabetes. , 2003, Diabetes/metabolism research and reviews.

[33]  T. Strom,et al.  Cytokine related therapies for autoimmune disease. , 2008, Current opinion in immunology.

[34]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[35]  Darrell M. Wilson,et al.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. , 2009, The New England journal of medicine.

[36]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[37]  C. Benoist,et al.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes , 2009, Nature Immunology.

[38]  R. Tisch,et al.  On the Pathogenicity of Autoantigen-Specific T-Cell Receptors , 2008, Diabetes.

[39]  S. Lieberman,et al.  A comprehensive guide to antibody and T-cell responses in type 1 diabetes. , 2003, Tissue antigens.

[40]  W. Suarez-Pinzon,et al.  Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. , 2005, Diabetes.

[41]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[42]  H. Chase,et al.  Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. , 1999, Diabetes care.

[43]  J. Krischer,et al.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. , 2005, Diabetes care.

[44]  J. Killestein Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[45]  J. Flier,et al.  Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts , 2007, Proceedings of the National Academy of Sciences.

[46]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[47]  J. Bluestone,et al.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.

[48]  L. Wen,et al.  Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. , 2007, The Journal of clinical investigation.

[49]  Jaakko Tuomilehto,et al.  Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study , 2008, The Lancet.

[50]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[51]  J. Kipnis,et al.  Extracellular Redox Modulation by Regulatory T Cells† , 2009, Nature chemical biology.

[52]  D. Bending,et al.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.

[53]  C. Benoist,et al.  Physiological β Cell Death Triggers Priming of Self-reactive T Cells by Dendritic Cells in a Type-1 Diabetes Model , 2003, The Journal of experimental medicine.

[54]  D. Greiner,et al.  TLR9-Signaling Pathways Are Involved in Kilham Rat Virus-Induced Autoimmune Diabetes in the Biobreeding Diabetes-Resistant Rat1 , 2007, The Journal of Immunology.

[55]  Y. Tochino,et al.  Breeding of a non-obese, diabetic strain of mice. , 1980, Jikken dobutsu. Experimental animals.

[56]  Camillo Ricordi,et al.  The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes , 1997, Nature Genetics.

[57]  J. Bluestone,et al.  Impairment of NK cell function by NKG2D modulation in NOD mice. , 2003, Immunity.

[58]  G. Eisenbarth,et al.  Interferon-α as a Mediator of Polyinosinic:Polycytidylic Acid–Induced Type 1 Diabetes , 2005 .

[59]  Mark S. Anderson,et al.  AIRE in the thymus and beyond. , 2009, Current opinion in immunology.

[60]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[61]  Jonathan H. Esensten,et al.  T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function1 , 2009, The Journal of Immunology.

[62]  M. Herrath Faculty Opinions recommendation of Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. , 2003 .

[63]  H. Waldmann,et al.  How do monoclonal antibodies induce tolerance? A role for infectious tolerance? , 1998, Annual review of immunology.

[64]  J. Todd,et al.  Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus , 1997, Nature Genetics.

[65]  M. Kenward,et al.  Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes , 2006, Diabetologia.

[66]  Mark S. Anderson,et al.  The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.

[67]  G. Eisenbarth,et al.  Conserved T cell receptor α-chain induces insulin autoantibodies , 2008, Proceedings of the National Academy of Sciences.

[68]  M. Ruth Normalization of obesity-associated insulin resistance through immunotherapy , 2010 .

[69]  C. Benoist,et al.  How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. , 2009, Immunity.

[70]  C. Delcourt,et al.  Analysis of mortality in French diabetic patients from death certificates: a comparative study. , 1999, Diabetes & metabolism.

[71]  M. Rewers,et al.  Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. , 2007, JAMA.

[72]  A. Laupacis,et al.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. , 1984, Science.

[73]  D. Greiner,et al.  The BB/Wor rat and the balance hypothesis of autoimmunity. , 1996, Diabetes/metabolism reviews.

[74]  R. Tisch,et al.  B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in FcγR Effector Functions1 , 2008, The Journal of Immunology.

[75]  U. Boggi,et al.  Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients , 2007, Proceedings of the National Academy of Sciences.

[76]  J. Krischer,et al.  Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. , 2006, Diabetes care.

[77]  G. Eisenbarth,et al.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice , 2002, Nature Medicine.

[78]  M. Mihatsch,et al.  Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.

[79]  M. Rewers,et al.  Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. , 2006, The Journal of clinical endocrinology and metabolism.

[80]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[81]  J. Bluestone,et al.  CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.

[82]  Bingye Han,et al.  Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. , 2005, The Journal of clinical investigation.

[83]  T. Tedder,et al.  Regulatory B cells as inhibitors of immune responses and inflammation , 2008, Immunological reviews.

[84]  P. Raskin,et al.  Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.

[85]  M. Redondo,et al.  Genetics of type 1A diabetes. , 2001, Recent progress in hormone research.

[86]  D. Kioussis,et al.  "Infectious" transplantation tolerance , 1993, Science.

[87]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[88]  P. Halban,et al.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. , 2008, The Journal of clinical endocrinology and metabolism.

[89]  M. Bhasin,et al.  Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice , 2008, Proceedings of the National Academy of Sciences.

[90]  G. Szot,et al.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.

[91]  G. Eisenbarth,et al.  Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. , 1985, Diabetes research.

[92]  S. Bonner-Weir,et al.  Dimorphic histopathology of long-standing childhood-onset diabetes , 2010, Diabetologia.

[93]  M. Dysken A Review of Recent Clinical Trials in the Treatment of Alzheimer's Dementia , 1987 .